SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-077909
Filing Date
2023-03-23
Accepted
2023-03-23 16:24:00
Documents
14
Period of Report
2023-03-23
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d266599d8k.htm   iXBRL 8-K 25532
2 EX-99.1 d266599dex991.htm EX-99.1 39353
6 GRAPHIC g266599g0321225433717.jpg GRAPHIC 3298
  Complete submission text file 0001193125-23-077909.txt   198621

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rgls-20230323.xsd EX-101.SCH 2857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgls-20230323_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgls-20230323_pre.xml EX-101.PRE 11266
8 EXTRACTED XBRL INSTANCE DOCUMENT d266599d8k_htm.xml XML 3359
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

IRS No.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35670 | Film No.: 23756551
SIC: 2834 Pharmaceutical Preparations